Day: September 20, 2023

Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disordersAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD). The project, named COGNI+, has been awarded the grant to deliver clinical candidates ready for IND enabling studies. The consortium includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK) and Stichting...

Hepsor SPV I Ltd, a Ontario-based subsidiary of Hepsor AS, made its second investment in the Canadian real estate market. An assembly of 3 properties was acquired in downtown Toronto at 164-168 Isabella Street together with Canadian partners. Elysium Isbella Limited Partnership was founded in order to develop the property in which, in addition to Hepsor and its Canadian partners, various Canadian and European investors also participate. Fasken (www.fasken.com), one of Canada’s largest law firms, advised Hepsor on structuring the deal. The goal of the first phase of the acquired development project is to assemble the 3 properties and apply and achieve zoning approvals to permit a residential hi-rise tower on a podium, with a projected Gross Floor Area of ca 42 000 sq meters (450,000 sq. ft). The assembly and zoning is expected to...

VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) — Eco Oro Minerals Corp. (CSE:EOM) (the “Company” or “Eco Oro”) is pleased to announce that it has entered into a credit agreement dated September 19, 2023 (the “Credit Agreement”) with Graywolfe Capital SEZC (the “Lender”) pursuant to which the Company may borrow up to US$6 million from the Lender (the “Facility”). The outstanding principal amount of the Facility will bear interest at a rate of 16.5% per annum and all obligations under the Facility will be secured by a general security interest over certain assets and properties of the Company. The funds provided from the Facility will be used to fund the Company’s working capital requirements and for general corporate purposes, including funding the costs relating to the Company’s ongoing arbitration under the auspices...

Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under allergen-induced allergic rhinitis conditions FDA Advisory Committee (PADAC), held in May 2023, recommended neffy approval based on current data set and without recommending additional trials FDA now requests repeat-dose study be completed prior to neffy approval as opposed to previously agreed-upon post-marketing requirement Well-capitalized with anticipated cash, cash equivalents and short-term investments on hand of approximately $195 million at the time of our anticipated neffy launch, if approved in 2H24, following our resubmission to the FDA in 1H24 SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to...

DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments,...

BRISBANE, Australia, Sept. 19, 2023 (GLOBE NEWSWIRE) — Allkem Limited (ASX/TSX: AKE, the Company) announces the following indicative key dates for the 2023 Annual General Meeting.Date Event27 September 2023 Last date for nomination of Directors6 October 2023 Release of Notice of Annual General Meeting8 November 2023 2023 Annual General MeetingShareholders will be provided with information on how to participate in the Annual General Meeting when the Notice of Meeting is released in October 2023. This release was authorised by Mr Martin Perez de Solay, CEO and Managing Director of Allkem Limited.  Allkem Limited ABN 31 112 589 910 Level 35, 71 Eagle StBrisbane, QLD 4000 Investor Relations & Media EnquiriesAndrew Barber +61 418 783 701Andrew.barber@allkem.co Connect info@allkem.co+61 7 3064 3600www.allkem.co      ...

Not for distribution to U.S. news wire services or for dissemination in the United States Toronto, Ontario, Sept. 19, 2023 (GLOBE NEWSWIRE) — Avante Corp. (TSX.V: XX) (OTC: ALXXF) (“Avante” or the “Company”) today announced that its board of directors has approved the acquisition (the “Acquisition”), through its subsidiary Avante International Inc (the “Purchaser”), of a 55% interest in North Star Support Group S.R.L. (“NSSG”), a highly reputed risk management and security company operating globally, for an aggregate purchase price of EUR1,300,000. The purchase price will be paid by way of a combination of cash in the amount of EUR1,200,000 and the issuance of 154,301 common shares in the capital of the Company. The transaction is expected to close on September 21, 2023. This strategic investment underscores Avante’s commitment...

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its public offering of 8,000,000 shares of its common stock at an initial price to the public of $12.50 per share. All of the shares are being offered by HilleVax. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. The offering is expected to close on September 22, 2023, subject to the satisfaction of customary closing conditions. In addition, HilleVax has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the initial price to the public, less underwriting discounts...